Hemab Therapeutics (NASDAQ:COAG) Rating Increased to Strong-Buy at Jefferies Financial Group

Hemab Therapeutics (NASDAQ:COAG) was upgraded by Jefferies Financial Group to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

COAG has been the subject of several other research reports. Evercore began coverage on shares of Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $50.00 target price for the company. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $36.00 price objective for the company. Wedbush assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $42.00 price objective on the stock. Finally, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy” and a consensus price target of $41.75.

Hemab Therapeutics Stock Performance

COAG stock opened at $27.84 on Tuesday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last posted its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were bought at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares in the company, valued at approximately $110,683,728. This trade represents a 77.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have purchased a total of 2,902,872 shares of company stock worth $53,769,784 over the last quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.